CAP-1002

Showing 1 posts of 1 posts found.

shutterstock_159488225

Capricor’s share price rockets up by 150% on Phase 2 Duchenne muscular dystrophy success

July 16, 2019
Manufacturing and Production, Research and Development CAP-1002, Capricor Therapeutics, Duchenne Muscular Dystrophy, pharma

Capricor Therapeutics has unveiled impactful new Phase 2 data for its investigational allogeneic cardiosphere-derived cell therapy CAP-1002 in the treatment …

Latest content